AR045530A1 - Peptidos y compuestos que se unen al receptor de trombopoyetina - Google Patents
Peptidos y compuestos que se unen al receptor de trombopoyetinaInfo
- Publication number
- AR045530A1 AR045530A1 ARP040103101A ARP040103101A AR045530A1 AR 045530 A1 AR045530 A1 AR 045530A1 AR P040103101 A ARP040103101 A AR P040103101A AR P040103101 A ARP040103101 A AR P040103101A AR 045530 A1 AR045530 A1 AR 045530A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- peptides
- compounds
- laarx10
- iegptlrq
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 abstract 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 abstract 4
- 102100034196 Thrombopoietin receptor Human genes 0.000 abstract 3
- 108010077895 Sarcosine Proteins 0.000 abstract 2
- 108010070774 Thrombopoietin Receptors Proteins 0.000 abstract 2
- 229940000635 beta-alanine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940043230 sarcosine Drugs 0.000 abstract 2
- 102100034195 Thrombopoietin Human genes 0.000 abstract 1
- 101710148535 Thrombopoietin receptor Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49874003P | 2003-08-28 | 2003-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045530A1 true AR045530A1 (es) | 2005-11-02 |
Family
ID=34272720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103101A AR045530A1 (es) | 2003-08-28 | 2004-08-27 | Peptidos y compuestos que se unen al receptor de trombopoyetina |
Country Status (32)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| EP1124961B9 (en) | 1998-10-23 | 2010-07-21 | Kirin-Amgen Inc. | Thrombopoietic compounds |
| NZ566812A (en) | 2002-09-18 | 2009-07-31 | Ortho Mcneil Pharm Inc | Methods of increasing platelet and hematopoietic stem cell production |
| US20040149235A1 (en) * | 2002-10-04 | 2004-08-05 | Pogue Albert S. | Apparatus and method for removal of waste from animal production facilities |
| EA009286B1 (ru) | 2003-08-28 | 2007-12-28 | Орто-Макнейл Фармасьютикал, Инк. | Пептиды и соединения, которые связываются с рецептором |
| US7723295B2 (en) * | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
| US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
| WO2007087428A2 (en) * | 2006-01-25 | 2007-08-02 | Amgen Inc. | Thrombopoietic compounds |
| MY151332A (en) * | 2006-02-14 | 2014-05-15 | Janssen Pharmaceutica Nv | Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia |
| CA2642389C (en) * | 2006-02-14 | 2014-05-06 | Janssen Pharmaceutica N.V. | Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia |
| US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
| KR20110015448A (ko) * | 2008-06-03 | 2011-02-15 | 얀센 파마슈티카 엔.브이. | 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드 |
| CN103635514B (zh) | 2011-06-23 | 2016-01-20 | 株式会社岛津制作所 | 支链型两亲性嵌段聚合物、使用其的分子聚集体及药物输送系统 |
| US12251424B2 (en) | 2017-07-26 | 2025-03-18 | Janssen Pharmaceutica Nv | Methods of protecting vascular integrity induced by targeted radiation therapy |
| US20200237872A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
| WO2020209920A2 (en) | 2019-01-25 | 2020-10-15 | Janssen Pharmaceutica Nv | Methods of mitigating toxic effects of vesicants and caustic gas |
| EP3914272B1 (en) | 2019-01-25 | 2024-03-06 | Janssen Pharmaceutica NV | Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments |
| EP4408984A1 (en) | 2021-10-01 | 2024-08-07 | Janssen Pharmaceutica NV | Methods of increasing progenitor cell production |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
| IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| US5571508A (en) | 1989-12-18 | 1996-11-05 | Amrad Corporation Limited | Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor |
| IT1241395B (it) | 1990-04-02 | 1994-01-10 | Eniricerche Spa | Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria |
| US5141851A (en) | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
| US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| PT644771E (pt) | 1992-06-11 | 2002-12-31 | Alkermes Inc | Sistema de entrega da droga eritropoietina |
| EP0673387B1 (en) | 1992-12-11 | 1999-09-22 | University Of Florida | Materials and methods for control of pests |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| GB2285446B (en) | 1994-01-03 | 1999-07-28 | Genentech Inc | Thrombopoietin |
| WO1995021920A1 (en) | 1994-02-14 | 1995-08-17 | Zymogenetics, Inc. | Hematopoietic protein and materials and methods for making it |
| WO1995021919A2 (en) | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| EP0723456A1 (en) | 1994-02-14 | 1996-07-31 | The University Of Washington | Methods for stimulating erythropoiesis using thrombopoietin |
| SG79882A1 (en) | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
| DE69503849T2 (de) | 1994-03-31 | 1999-04-01 | Amgen Inc., Thousand Oaks, Calif. | Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten |
| US5571686A (en) | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
| CA2180021A1 (en) * | 1994-11-04 | 1996-05-17 | Yoichi Kawashima | Novel 1,3-dialkylurea derivatives having a hydroxyl group |
| US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
| AU4163196A (en) | 1994-11-30 | 1996-06-19 | Zymogenetics Inc. | Low molecular weight thrombopoietin |
| JP3763846B2 (ja) | 1995-04-26 | 2006-04-05 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| EP1961760A3 (en) * | 1995-06-07 | 2008-09-03 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US6060052A (en) | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
| US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| EP1223944B1 (en) | 1999-09-24 | 2007-01-03 | SmithKline Beecham Corporation | Thrombopoietin mimetics |
| PL205949B1 (pl) * | 2000-12-22 | 2010-06-30 | Ipsen Mfg Ireland Ltd | Sposób wytwarzania peptydu |
| WO2002078612A2 (en) | 2001-04-02 | 2002-10-10 | Euro-Celtique S.A. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
| NZ566812A (en) * | 2002-09-18 | 2009-07-31 | Ortho Mcneil Pharm Inc | Methods of increasing platelet and hematopoietic stem cell production |
| EA009286B1 (ru) | 2003-08-28 | 2007-12-28 | Орто-Макнейл Фармасьютикал, Инк. | Пептиды и соединения, которые связываются с рецептором |
-
2004
- 2004-08-13 EA EA200600477A patent/EA009286B1/ru unknown
- 2004-08-13 HR HRP20170810TT patent/HRP20170810T1/hr unknown
- 2004-08-13 RS YU20060141A patent/RS56387B1/sr unknown
- 2004-08-13 ES ES04781153.4T patent/ES2626107T3/es not_active Expired - Lifetime
- 2004-08-13 HU HUE04781153A patent/HUE032370T2/en unknown
- 2004-08-13 RS YUP-2006/0141A patent/RS20060141A/sr unknown
- 2004-08-13 PL PL04781153T patent/PL1675606T3/pl unknown
- 2004-08-13 DK DK04781153.4T patent/DK1675606T3/en active
- 2004-08-13 LT LTEP04781153.4T patent/LT1675606T/lt unknown
- 2004-08-13 PT PT47811534T patent/PT1675606T/pt unknown
- 2004-08-13 WO PCT/US2004/026422 patent/WO2005023834A2/en not_active Ceased
- 2004-08-13 MX MXPA06002292A patent/MXPA06002292A/es active IP Right Grant
- 2004-08-13 AU AU2004270656A patent/AU2004270656B2/en not_active Expired
- 2004-08-13 SI SI200432391A patent/SI1675606T1/sl unknown
- 2004-08-13 US US10/918,561 patent/US7576056B2/en not_active Expired - Lifetime
- 2004-08-13 KR KR1020127014067A patent/KR20120078742A/ko not_active Withdrawn
- 2004-08-13 CN CN2004800314520A patent/CN1871022B/zh not_active Expired - Lifetime
- 2004-08-13 SG SG200701488-9A patent/SG131110A1/en unknown
- 2004-08-13 JP JP2006524705A patent/JP4848277B2/ja not_active Expired - Lifetime
- 2004-08-13 CA CA2537421A patent/CA2537421C/en not_active Expired - Lifetime
- 2004-08-13 BR BRPI0414008A patent/BRPI0414008B8/pt active IP Right Grant
- 2004-08-13 KR KR1020067003755A patent/KR101183875B1/ko not_active Expired - Fee Related
- 2004-08-13 NZ NZ545455A patent/NZ545455A/en not_active IP Right Cessation
- 2004-08-13 UA UAA200602523A patent/UA82710C2/uk unknown
- 2004-08-13 CN CN201110134196.XA patent/CN102241742B/zh not_active Expired - Lifetime
- 2004-08-13 ME MEP-2008-485A patent/ME00313B/me unknown
- 2004-08-13 EP EP04781153.4A patent/EP1675606B1/en not_active Expired - Lifetime
- 2004-08-27 TW TW093125674A patent/TWI348375B/zh not_active IP Right Cessation
- 2004-08-27 AR ARP040103101A patent/AR045530A1/es active IP Right Grant
-
2006
- 2006-02-14 IS IS8300A patent/IS8300A/is unknown
- 2006-02-24 EC EC2006006396A patent/ECSP066396A/es unknown
- 2006-02-27 IL IL173965A patent/IL173965A/en active IP Right Grant
- 2006-03-24 NO NO20061346A patent/NO344233B1/no unknown
- 2006-03-27 ZA ZA200602495A patent/ZA200602495B/en unknown
-
2017
- 2017-06-15 CY CY20171100628T patent/CY1118965T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045530A1 (es) | Peptidos y compuestos que se unen al receptor de trombopoyetina | |
| JP7257951B2 (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| RU2012133522A (ru) | Новое применение соединений ил-1 бета | |
| MY208749A (en) | Biligand drug conjugates and uses thereof | |
| JP2021505661A5 (cg-RX-API-DMAC7.html) | ||
| CY1116463T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| RU2013120311A (ru) | Терапевтическое применение агониста tlr и комбинированная терапия | |
| EA200400737A1 (ru) | Препарат аминокислот и рибофлавина, применимый для уменьшения токсического действия цитотоксической химиотерапии | |
| CA2444821A1 (en) | Combination therapy using anti-angiogenic agents and tnfa | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| EA026870B1 (ru) | Комбинация и фармацевтическая композиция для лечения опухолей | |
| PE20160994A1 (es) | Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento | |
| ES2204640T3 (es) | Preparado farmaceutico con contenido en proteinas. | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| WO2022174064A3 (en) | Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer | |
| MX2024014994A (es) | Macrociclos de indazol y su uso | |
| KR20120061841A (ko) | 동통 억제용 의약 조성물 | |
| AR078170A1 (es) | Metodos para el tratamiento de tumores cerebrales | |
| PE20070416A1 (es) | Compuestos peptidicos como agonistas del receptor de trombopoyetina | |
| NZ703919A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| AU2002221622B2 (en) | Antitumor therapy comprising distamycin derivatives | |
| CN1345336A (zh) | 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途 | |
| SI2167038T1 (en) | The use of a TACI-Ig fusion protein, such as atacicept, for the manufacture of a medicament for the treatment of erythematous lupus | |
| CN103254317A (zh) | 一种抗cd20单克隆抗体-海兔毒素偶联物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |